Cochlear (COH.AX) Azione Prezzo
Cochlear Prezzo
Negli ultimi 19 anni Cochlear ha aumentato il fatturato del 7,8% all'anno, raggiungendo 2,33 miliardi AUD. L'utile per azione è cresciuto del 1,2% all'anno negli ultimi 19 anni. Per Cochlear, il margine netto del 6,3% risulta in calo rispetto al 17,6% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 3,77%. Il payout ratio è pari a circa il 95% degli utili. Il dividendo è cresciuto del 6,5% all'anno negli ultimi 19 anni. Il target di prezzo di consenso a 12 mesi per Cochlear è 252,40 AUD, circa il 62,3% sopra il prezzo attuale di mercato. Su 19 analisti, 8 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Cochlear Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Cochlear Azione e analisi azionaria
Domande frequenti sull'azione Cochlear
Cochlear Ltd operates under a distinctive business model. As a global leader in the development and manufacturing of hearing solutions, the company primarily focuses on designing, producing, and marketing cochlear implant devices. Cochlear implants are electronic devices that provide a sense of sound to individuals with severe hearing loss or deafness. With a commitment to continuous innovation and superior quality, Cochlear Ltd offers a wide range of products and services that cater to the needs of patients, healthcare professionals, and hearing implant clinics worldwide. Through its robust business model, Cochlear Ltd aims to improve the lives of individuals with hearing challenges by providing cutting-edge and life-changing hearing solutions.
Cochlear Ltd is primarily active in the healthcare and medical device industries.
The main competitors of Cochlear Ltd in the market include major companies like Medtronic, Sonova Holding AG, and William Demant Holding A/S.
Cochlear Ltd is an Australian medical device company specializing in hearing implant solutions. Founded in 1981, it has a rich history and remarkable achievements in the field of implantable hearing devices. Cochlear is globally recognized for its groundbreaking advancements in the development and commercialization of cochlear implant technology. By providing solutions for people with profound hearing loss, Cochlear has improved the lives of millions worldwide. With a strong commitment to innovation and a dedicated team of experts, Cochlear remains at the forefront of the industry, continuously striving to enhance hearing experiences and transform lives through its state-of-the-art products and services.
Cochlear Ltd has achieved several significant milestones. One of the notable milestones includes the development and introduction of the world's first commercially successful cochlear implant in 1982. This breakthrough technology revolutionized the treatment of hearing loss for millions of people worldwide. Another key milestone for Cochlear Ltd was the successful launch of the Nucleus 6 Sound Processor, which offered enhanced hearing performance and wireless connectivity options. The company also made significant progress in expanding its global footprint, establishing subsidiaries and partnerships in different regions. Additionally, Cochlear Ltd received numerous industry recognitions and awards for its innovative products and contribution to the field of hearing healthcare.
Cochlear Ltd is primarily present in various countries and regions worldwide. The company operates in over 100 countries, including but not limited to Australia, the United States, Europe, Asia-Pacific, and Latin America. With its global presence, Cochlear Ltd has established itself as a leading provider of innovative hearing solutions and implantable hearing devices. Through its extensive network and collaborations, the company strives to enhance the lives of individuals with hearing loss across the world by providing advanced hearing technology and support.
Cochlear Ltd represents a strong set of values and corporate philosophy. The company is committed to improving the lives of people with hearing loss by providing innovative and reliable solutions. Cochlear believes in putting their customers first and delivering exceptional quality products and services. With a focus on continuous improvement, the company is dedicated to research and development to drive technological advancements in the field of hearing implants. Cochlear's corporate philosophy is centered around integrity, collaboration, and social responsibility. By embracing diversity and fostering a culture of inclusivity, Cochlear strives to make a positive impact on individuals and communities worldwide.
Gli analisti fissano attualmente un prezzo obiettivo medio di 265,71 AUD per l’azione Cochlear (mediana: 252,40 AUD), pari a +75,6 % rispetto all’ultimo prezzo. Il consenso si basa su 19 giudizi di analisti.
19 analisti valutano attualmente l’azione Cochlear: 9 raccomandano l’acquisto, 9 la tenuta e 1 la vendita.
Convertita al tasso di cambio attuale, l’azione Cochlear quota 95,63 EUR (155,47 AUD).
L’azione Cochlear (COH.AX) è quotata su 7 borse, tra cui: SIX (Zürich) (COH.SW), ASX (COH.AX), Frankfurt (OC5.F), München (OC5.MU), Düsseldorf (OC5.DU), Hamburg (OC5.HM).
Cochlear Ltd is a leading provider of innovative medical solutions for people with hearing loss. The company is headquartered in Sydney, Australia and operates in over 100 countries worldwide. Cochlear specializes in imitating the functionality of the human ear to provide a better hearing experience for those with hearing loss. They offer a wide range of products and services including cochlear implants, audioprocessors, cochlear replacement parts, and hearing aids. Cochlear implants are one of the company's main products, designed to help those with severe to profound hearing loss regain their ability to hear. The implant is an electronic device that bypasses the inner ear by sending signals directly to the auditory nerve. In addition to cochlear implants and audioprocessors, Cochlear also offers wireless accessory devices such as TV streamers to enhance the listening experience. They have a dedicated department for manufacturing hearing aids called "Cochlear Devices," which are designed for individuals with mild to moderate hearing loss. The company is always working on new technologies to improve the listening experience for individuals with hearing loss, including their latest innovation, the Cochlear sound processor, which utilizes artificial intelligence to automatically adapt to different environments for optimal sound quality. Cochlear provides a range of services to support their customers, including training and support for healthcare professionals who implant or adjust Cochlear devices. They collaborate with customers, clinics, research institutions, and universities to develop the latest advancements in technology to improve the lives of individuals with hearing loss. Cochlear's business model is focused on promoting health and well-being, providing innovative hearing device and implant technologies, and comprehensive services to ensure an excellent patient experience. They are committed to playing a leading role in the treatment of hearing loss and helping people worldwide overcome their hearing challenges.
Il fatturato di Cochlear ammonta a 2,33 miliardi AUD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto di Cochlear ammonta a 147,30 Mio. AUD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Cochlear è attualmente 69,03. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Cochlear.
Il rapporto prezzo/fatturato (P/S) di Cochlear è attualmente 4,35. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Cochlear.
Il Quality Score AlleAktien per Cochlear è 5/10.
L'ISIN di Cochlear è AU000000COH5. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Cochlear è 898321. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Cochlear è COH.AX. Con questo simbolo di borsa vengono negoziate le azioni Cochlear in borsa.
Azione Cochlear
Gruppo di pari di Cochlear
Cochlear Ticker
Cochlear FIGI
Altre metriche e analisi di Cochlear in Deep Dive.
La nostra analisi azionaria dell'azione Cochlear include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Cochlear. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: